MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KALMAN, T. I.
Right arrow Articles by BARDOS, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KALMAN, T. I.
Right arrow Articles by BARDOS, T. J.

Molecular Pharmacology, Vol 6, 621-630, Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics

Enzymatic Studies Relating to the Mode of Action of 5-Mercapto-2'-deoxyuridine

THOMAS I. KALMAN 1 and THOMAs J. BARDOS 1

1 Departments of Biochemical Pharmacology and Medicinal Chemistry, Faculty of Health Sciences, State University of New York at Buffalo, Buffalo, New York 14214

Kinetic studies of the effects of 5-mercapto-2'-deoxyuridine (MUdR) and some of its derivatives on the thymidine kinase and thymidylate synthetase of Escherichia coli B are presented. It was found that MUdR and its S-methyl derivative are phosphorylated by thymidine kinase, while other derivatives, including the disulfide, are not. In crude extracts of E. coil B, thymidylate synthetase was inhibited by MUdR (but not the S-methyl derivative) in the presence of ATP only. MUdR 5'-monophosphate (MUdRP) was prepared by enzymatic phosphorylation of MUdR and found to be a potent inhibitor of purified E. coil B thymidylate synthetase (Ki = 4.0 x 10-8 M; Ki/Km = 0.0085), competitive with the substrate, deoxyuridylate. The "anomalous" strong binding of MUdRP to this enzyme is discussed.

The results of these studies are consistent with the hypothesis that the mode of action of MUdR involves the metabolic activation of the analogue via phosphorylation by thymidine kinase and subsequent inhibition of thymidylate synthetase by the active form, MUdRP, resulting in the inhibition of DNA synthesis.

Note:
ACKNOWLEDGMENTS The technical assistance of Mrs. M. Hsiao and Mr. M. Anderson in part of this work is appreciated.

Submitted on April 13, 1970







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics